NEPHROS INC
About NEPHROS INC
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $18.8M
- Net income
- $1.2M
- Total assets
- $13.6M
- Market cap
- $37.1M
- Gross margin
- 61.9%
- Operating margin
- 6.1%
- Net margin
- 6.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $18.8M
- Cost of revenue
- $7.2M
- Gross profit
- $11.6M
- Operating expenses
- $10.5M
- Operating income
- $1.1M
- Income tax
- $12.0K
- Net income
- $1.2M
- EPS (basic)
- $0.11
- EPS (diluted)
- $0.11
Balance sheet
- Total assets
- $13.6M
- Current assets
- $11.2M
- Total liabilities
- $3.4M
- Current liabilities
- $2.8M
- Shareholders’ equity
- $10.2M
Cash flow
- Operating cash flow
- $1.6M
- Investing cash flow
- -$1.6M
- Financing cash flow
- -$5.0K
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $37.1M
- P/E ratio
- 30.8
- EPS (diluted)
- $0.11
- Shares outstanding
- 11.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 21, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.2M in FY2025.
- Revenue grew 81% from FY2021 to FY2025.
- Gross margin of 61.9%, net margin 6.4%.
- Trading 41% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 30.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NEPHROS INC.
Write a review
News about NEPHROS INC
News & sentiment via Polygon.io
